- SOHM, Inc. launches a new AI team on April 7, 2025, to advance genome editing.
- The team will enhance the ABBIE system and design novel RNA-guided tools.
- AI will optimize the specificity and efficiency of genome editing applications.
- SOHM aims for breakthroughs in gene therapy, agriculture, and synthetic biology.
- The AI team will also develop custom exosomes for targeted drug delivery.
SOHM, Inc. Forms New AI Team to Advance Genome Editing and Therapeutic Delivery
SOHM, Inc. (OTC PINK:SHMN), a company specializing in generic drugs and gene-editing tools, announced the launch of a dedicated artificial intelligence (AI) team on Monday, April 7, 2025. This strategic initiative aims to accelerate the development and capabilities of SOHM’s ABBIE (A Binding-based Integrase Enzyme) system and to innovate the design of novel guide RNAs and other RNA-guided Integrase fusion proteins, marking a significant investment in the future of genetic engineering.
The newly formed AI team will leverage advanced machine learning algorithms to optimize the design of guide RNAs and Integrase-dCas fusion proteins associated with the ABBIE system. This integration of AI into SOHM’s research and development processes is expected to significantly enhance the specificity, efficiency, and versatility of genome editing applications, paving the way for potential breakthroughs in various sectors including gene therapy, agriculture, and synthetic biology.
“Our new AI team represents a significant investment in the future of genetic engineering,” stated Dr. David Aguilar, COO of SOHM Inc. “By harnessing the power of AI, we aim to accelerate our research and development processes, ultimately leading to more effective and targeted genome editing solutions. Aiding the ABBIE system is just the beginning of what we hope to achieve with this cutting-edge technology.”
Beyond refining the ABBIE system, the AI team will also explore other promising avenues within the genome editing landscape. This includes the development of next-generation genome editing systems capable of targeting previously inaccessible genomic regions and enhancing the safety profiles of existing gene editing tools. Additionally, a key focus will be on creating engineered cells that produce custom exosomes with pharmaceutical properties. This project aims to engineer exosomes as highly targeted delivery vehicles for therapeutic agents, offering a novel approach to treating a wide range of diseases at the cellular level.
The potential applications of these custom exosomes are vast, spanning areas such as cancer therapy, regenerative medicine, and immunotherapy. By combining AI-driven insights with ABBIE-based cell engineering, SOHM Inc. intends to design exosomes that can efficiently transport drugs, genes, or RNA molecules to specific tissues within the body. This targeted delivery system has the potential to significantly improve the efficacy and safety of various treatments.
“AI has the potential to transform how we approach genetic engineering and therapeutics,” added Aguilar. “Our focus on the ABBIE system and custom exosomes is just the start. We are committed to pushing the boundaries of what’s possible in genome editing and therapeutic delivery.”
As SOHM Inc. embarks on this new phase of research and development, the company reaffirms its commitment to advancing scientific knowledge and improving human health through innovative biotechnology solutions. The establishment of this dedicated AI team represents a significant milestone in SOHM’s ongoing efforts to be a leader in genomic research and development.